Breast diseases

PubMed Free Full Text

Breast cancer treatment: monoclonal antibodies

Asia-Pacific

• Drug Safety
  • Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel [2023]

Australia

• Australian Prescriber
  • Trastuzumab deruxtecan for breast cancer [2022]

Austria

• Oncologist
  • Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer [2012]

Canada

• Canada's Drug Agency
  • Trastuzumab deruxtecan (Enhertu) [2023]
  • Pertuzumab (Perjeta) [2022]

• Current Oncology
  • Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective [2023]
  • Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain [2022]

Canada, Europe

• Breast Cancer
  • Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy [2024]

Canada, Europe, United States

• ESMO Open
  • Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer [2022]

China

• Translational Breast Cancer Research
  • A round table discussion: clinical landscape of trastuzumab deruxtecan in breast cancer: a retrospective and prospective view [2022]

Europe

• ESMO Open
  • Flexible care in breast cancer [2021]

• European Medicines Agency
  • Perjeta
  • Herceptin
  • Enhertu

Finland

• European Journal of Health Economics
  • Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland [2024]

France

• Haute Autorité de Santé
  • PHESGO (pertuzumab, trastuzumab) [2021]

Germany

• BMC Cancer
  • Trastuzumab in advanced breast cancer - a decade of experience in Germany [2014]

• Breast Care
  • Adopting Guidelines into Clinical Practice: Implementation of Trastuzumab in the Adjuvant Treatment of Breast Cancer in Lower Saxony, Germany, in 2007 [2011]

Hong Kong

• Hong Kong Medical Journal
  • Cost-minimisation analysis of intravenous versus subcutaneous trastuzumab regimen for breast cancer management in Hong Kong [2023]

India

• JCO Global Oncology
  • Cost Effectiveness of Trastuzumab for Management of Breast Cancer in India [2020]

Indonesia

• PLoS ONE
  • Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis [2024]

International

• Biomedicines
  • Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer [2022]

• Critical Reviews in Oncology/Hematology
  • Trastuzumab deruxtecan in breast cancer [2024]
  • Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis [2023]

• Current Breast Cancer Reports
  • Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer [2017]

• Expert Review of Pharmacoeconomics & Outcomes Research
  • Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review [2024]
  • Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment [2021]

• Frontiers in Oncology
  • Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials [2022]

• Frontiers in Pharmacology
  • Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis [2023]

• International Journal of Molecular Sciences
  • Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review [2025]

• PLoS ONE
  • The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis [2022]

• Revista Peruana de Medicina Experimental y Salud Pu´blica
  • Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis [2024]

Iran

• BMC Health Services Research
  • Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience [2025]

• PharmacoEconomics
  • Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy [2018]

Italy

• ESMO Open
  • Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients [2023]

• Oncologist
  • Cardiovascular risk after adjuvant trastuzumab in early breast cancer: an Italian population-based cohort study [2020]

Japan

• Breast Cancer
  • Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines [2024]

• Breast Cancer Research and Treatment
  • A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study [2019]

• Molecular and Clinical Oncology
  • Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan [2015]

Netherlands

• Breast
  • Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival [2022]

• Breast Cancer Research and Treatment
  • Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry [2021]

New Zealand

• PLoS Medicine
  • Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis [2016]

Philippines

• BMC Health Services Research
  • Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines [2019]

Singapore

• Annals Academy of Medicine Singapore
  • Singapore Cancer Network (SCAN) Guidelines for Adjuvant Trastuzumab Use in Early Stage HER2 Positive Breast Cancer [2015]

Spain

• Clinical and Translational Oncology
  • Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management [2024]

United Kingdom

• European Journal of Cancer
  • Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data [2024]

• Health Technology Assessment
  • Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT [2020]

• National Institute for Health and Care Excellence
  • Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal) [2025]
  • Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [2024]
  • Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [2023]
  • Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [2021]
  • Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [2020]
  • Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer [2019]
  • Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer [2018]
  • Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane [2017]
  • Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer [2016]
  • Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab [2013]

• PharmacoEconomics - Open
  • Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal [2023]

United States

• American Journal of Managed Care
  • Integrating Trastuzumab Biosimilars and HER2-Directed Therapies into HER2-Positive Breast Cancer Management [2020]

• Cancer Treatment Reviews
  • Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan [2024]

• JNCCN
  • Initiation of Trastuzumab by Women Younger Than 64 Years for Adjuvant Treatment of Stage I-III Breast Cancer [2018]

• Journal of Clinical Oncology
  • Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter [2016]

• npj Breast Cancer
  • Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond [2020]

• StatPearls
  • Trastuzumab

Uruguay

• Medicine
  • Trastuzumab-induced cardiotoxicity in early breast cancer over a 10-year period in Uruguay [2022]

Vietnam

• PLoS ONE
  • Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam [2024]

{Related topics}

• Topic
  • Breast cancer treatment